🚀 VC round data is live in beta, check it out!
Lumosa Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Lumosa Therapeutics and similar public comparables like Valneva, SELLAS Life Sciences, Geron, SPIMACO - ADDWAEIH and more.
Lumosa Therapeutics Overview
About Lumosa Therapeutics
Lumosa Therapeutics Co Ltd develops new drugs. The company is engaged in the development of drugs for unmet medical needs in the fields of oncology and Neuroscience. Geographically, it derives a majority of its revenue from Asia and also has a presence in Taiwan, Europe, Asia, and America. The product pipeline of the company is Neuroscience, which includes LT 1001 for Postoperative Pain, LT 3001 for Acute Ischemic Stroke, LT 5001 for Uremic Pruritus, LT 6001 for Neurological disorder, and Oncology including LT 2003 for Solid Tumor. It generates revenue from sales of goods.
Founded
2000
HQ
Employees
34
Website
Sectors
Financials (FY)
EV
$919M
Lumosa Therapeutics Financials
Lumosa Therapeutics reported last fiscal year revenue of $1M and negative EBITDA of ($11M).
In the same fiscal year, Lumosa Therapeutics generated $686K in gross profit, ($11M) in EBITDA losses, and had net loss of ($11M).
Revenue (LTM)
Lumosa Therapeutics P&L
In the most recent fiscal year, Lumosa Therapeutics reported revenue of $1M and EBITDA of ($11M).
Lumosa Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $1M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $686K | XXX | XXX | XXX |
| Gross Margin | — | XXX | 61% | XXX | XXX | XXX |
| EBITDA | — | XXX | ($11M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (935%) | XXX | XXX | XXX |
| EBIT Margin | — | XXX | (931%) | XXX | XXX | XXX |
| Net Profit | — | XXX | ($11M) | XXX | XXX | XXX |
| Net Margin | — | XXX | (950%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Lumosa Therapeutics Stock Performance
Lumosa Therapeutics has current market cap of $945M, and enterprise value of $919M.
Market Cap Evolution
Lumosa Therapeutics' stock price is $5.61.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $919M | $945M | (0.9%) | XXX | XXX | XXX | $-0.06 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialLumosa Therapeutics Valuation Multiples
Lumosa Therapeutics trades at 818.4x EV/Revenue multiple, and (87.5x) EV/EBITDA.
EV / Revenue (LTM)
Lumosa Therapeutics Financial Valuation Multiples
As of March 7, 2026, Lumosa Therapeutics has market cap of $945M and EV of $919M.
Equity research analysts estimate Lumosa Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Lumosa Therapeutics has a P/E ratio of (88.5x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $945M | XXX | $945M | XXX | XXX | XXX |
| EV (current) | $919M | XXX | $919M | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 818.4x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (87.5x) | XXX | XXX | XXX |
| EV/EBIT | — | XXX | (87.9x) | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 1340.6x | XXX | XXX | XXX |
| P/E | — | XXX | (88.5x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (81.2x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Lumosa Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Lumosa Therapeutics Margins & Growth Rates
Lumosa Therapeutics' revenue in the last fiscal year declined by (9%).
Lumosa Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | (9%) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (935%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (22%) | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 32% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 110% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 850% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 992% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Lumosa Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Valneva | XXX | XXX | XXX | XXX | XXX | XXX |
| SELLAS Life Sciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Geron | XXX | XXX | XXX | XXX | XXX | XXX |
| SPIMACO - ADDWAEIH | XXX | XXX | XXX | XXX | XXX | XXX |
| Theravance | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Lumosa Therapeutics M&A Activity
Lumosa Therapeutics acquired XXX companies to date.
Last acquisition by Lumosa Therapeutics was on XXXXXXXX, XXXXX. Lumosa Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Lumosa Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialLumosa Therapeutics Investment Activity
Lumosa Therapeutics invested in XXX companies to date.
Lumosa Therapeutics made its latest investment on XXXXXXXX, XXXXX. Lumosa Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Lumosa Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Lumosa Therapeutics
| When was Lumosa Therapeutics founded? | Lumosa Therapeutics was founded in 2000. |
| Where is Lumosa Therapeutics headquartered? | Lumosa Therapeutics is headquartered in Taiwan. |
| How many employees does Lumosa Therapeutics have? | As of today, Lumosa Therapeutics has over 34 employees. |
| Is Lumosa Therapeutics publicly listed? | Yes, Lumosa Therapeutics is a public company listed on Taipei Exchange. |
| What is the stock symbol of Lumosa Therapeutics? | Lumosa Therapeutics trades under 6535 ticker. |
| When did Lumosa Therapeutics go public? | Lumosa Therapeutics went public in 2015. |
| Who are competitors of Lumosa Therapeutics? | Lumosa Therapeutics main competitors are Valneva, SELLAS Life Sciences, Geron, SPIMACO - ADDWAEIH. |
| What is the current market cap of Lumosa Therapeutics? | Lumosa Therapeutics' current market cap is $945M. |
| What is the current revenue of Lumosa Therapeutics? | Lumosa Therapeutics' last fiscal year revenue is $1M. |
| What is the current EV/Revenue multiple of Lumosa Therapeutics? | Current revenue multiple of Lumosa Therapeutics is 818.4x. |
| Is Lumosa Therapeutics profitable? | No, Lumosa Therapeutics is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.